Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis.
5 affiliations
- 1Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
- 2Cancer Center of Peking University Third Hospital, Beijing, China.
- 3Beijing Key Laboratory of Interdisciplinary Research in Gastrointestinal Oncology (BLGO), Peking University Third Hospital, Beijing, China.
- 4Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
- 5Department of Radiation Oncology, Cancer Center of Peking University Third Hospital, Peking University Third Hospital, Beijing, China.
Abstract
Background
Ovarian cancer (OC) remains the most lethal gynaecological malignancy, and acquired resistance to PARP inhibitors such as olaparib represents a major clinical challenge. Although dysregulation of iron metabolism has been implicated in tumorigenesis, the specific role of the iron exporter SLC40A1 (ferroportin, FPN) in mediating olaparib resistance remains poorly understood. The study aimed to elucidate the clinical significance of FPN deficiency and to explore therapeutic strategies for reversing olaparib resistance.Methods
FPN expression was evaluated in OC samples from a clinical cohort of 19 patients, stratified by olaparib responsiveness, to determine its prognostic value. Functional mechanisms were investigated using multiple OC cell lines, patient-derived organoids (PDOs), and mouse xenograft models. We integrated analyses of iron homeostasis, ROS dynamics, DNA repair capacity, and innate immune signaling, with a focus on the cGAS-STING-STAT3 signaling cascade. The therapeutic potential of combining olaparib with the ferroptosis inducer erastin or the STING inhibitor C-176 was assessed as a strategy to overcome FPN deficiency-driven resistance.Results
Clinically, FPN expression was significantly downregulated in olaparib-resistant tissues compared with sensitive controls (p < 0.05), and low FPN levels were strongly associated with poor therapeutic outcomes. Mechanistically, FPN deficiency promoted intracellular iron accumulation and ROS generation, which led to increased ferroptosis vulnerability, impaired homologous recombination repair (HRR) and concomitant activation of the cGAS-STING-STAT3 inflammatory axis, thereby driving olaparib resistance. Notably, in vivo studies demonstrated that combining olaparib with either erastin or C-176 significantly suppressed tumour growth and restored drug sensitivity compared with monotherapy (p < 0.01), supporting the translational potential of targeting this axis.Conclusions
Our study establishes a clinically relevant mechanistic connection between ferroportin deficiency and cGAS-STING-STAT3-mediated olaparib resistance in OC. We identify the FPN-ROS-cGAS-STING-STAT3 axis as an actionable vulnerability in resistant OC, indicating that this pathway is a promising therapeutic target to overcome olaparib resistance.Highlights
FPN loss drives olaparib resistance and predicts poor outcomes in ovarian cancer. FPN loss causes iron and ROS accumulation, impairing HRR and activating the cGAS-STING-STAT3 axis. The cGAS-STING-STAT3 pro-survival program drives olaparib resistance. STING inhibition restores olaparib sensitivity in resistant ovarian cancer.
Related
- Comparison of Survival Outcomes with First-Line PARP Inhibitor Maintenance According to BRCA Mutation and Homologous Recombination Deficiency Status in Advanced Ovarian Cancer: A Single-Center Retrospective Cohort Study
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- SLC7A11 suppresses paclitaxel resistance and improves survival via the KLF2 regulatory axis associated with autophagy in ovarian cancer.
- Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
- Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
BibTeX
@article{song2026ferroportin,
title = {{Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis.}},
author = {Jiagui Song and Zhengyang Guo and Decao Yang and Ping Yu and Yinjia Li and Zhuhui Yuan and Xiaojuan Ma and Xianlong Li and Hongyan Guo and Lixiang Xue and Tong Liu},
journal = {Clinical and translational medicine},
year = {2026},
month = nov,
doi = {10.1002/ctm2.70885},
url = {https://europepmc.org/article/MED/42968661},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis.
AU - Jiagui Song
AU - Zhengyang Guo
AU - Decao Yang
AU - Ping Yu
AU - Yinjia Li
AU - Zhuhui Yuan
AU - Xiaojuan Ma
AU - Xianlong Li
AU - Hongyan Guo
AU - Lixiang Xue
AU - Tong Liu
PY - 2026
DA - 2026/11/01
JO - Clinical and translational medicine
DO - 10.1002/ctm2.70885
UR - https://europepmc.org/article/MED/42968661
AB - Background Ovarian cancer (OC) remains the most lethal gynaecological malignancy, and acquired resistance to PARP inhibitors such as olaparib represents a major clinical challenge. Although dysregulation of iron metabolism has been implicated in tumorigenesis, the specific role of the iron exporter SLC40A1 (ferroportin, FPN) in mediating olaparib resistance remains poorly understood. The study aimed to elucidate the clinical significance of FPN deficiency and to explore therapeutic strategies for reversing olaparib resistance.Methods FPN expression was evaluated in OC samples from a clinical cohort of 19 patients, stratified by olaparib responsiveness, to determine its prognostic value. Functional mechanisms were investigated using multiple OC cell lines, patient-derived organoids (PDOs), and mouse xenograft models. We integrated analyses of iron homeostasis, ROS dynamics, DNA repair capacity, and innate immune signaling, with a focus on the cGAS-STING-STAT3 signaling cascade. The therapeutic potential of combining olaparib with the ferroptosis inducer erastin or the STING inhibitor C-176 was assessed as a strategy to overcome FPN deficiency-driven resistance.Results Clinically, FPN expression was significantly downregulated in olaparib-resistant tissues compared with sensitive controls (p < 0.05), and low FPN levels were strongly associated with poor therapeutic outcomes. Mechanistically, FPN deficiency promoted intracellular iron accumulation and ROS generation, which led to increased ferroptosis vulnerability, impaired homologous recombination repair (HRR) and concomitant activation of the cGAS-STING-STAT3 inflammatory axis, thereby driving olaparib resistance. Notably, in vivo studies demonstrated that combining olaparib with either erastin or C-176 significantly suppressed tumour growth and restored drug sensitivity compared with monotherapy (p < 0.01), supporting the translational potential of targeting this axis.Conclusions Our study establishes a clinically relevant mechanistic connection between ferroportin deficiency and cGAS-STING-STAT3-mediated olaparib resistance in OC. We identify the FPN-ROS-cGAS-STING-STAT3 axis as an actionable vulnerability in resistant OC, indicating that this pathway is a promising therapeutic target to overcome olaparib resistance.Highlights FPN loss drives olaparib resistance and predicts poor outcomes in ovarian cancer. FPN loss causes iron and ROS accumulation, impairing HRR and activating the cGAS-STING-STAT3 axis. The cGAS-STING-STAT3 pro-survival program drives olaparib resistance. STING inhibition restores olaparib sensitivity in resistant ovarian cancer.
SN - 2001-1326
ER -